Literature DB >> 3919934

Abdominopelvic radiotherapy in ovarian cancer. A 10-year experience.

A J Dembo.   

Abstract

A 10-year experience is presented of the use of postoperative abdominopelvic radiotherapy in 415 patients with epithelial ovarian cancer, Stages I, II, and III. Five- and 10-year survival and relapse-free data are reported by stage and residuum. Risk of relapse was analyzed in detail according to histologic features, residuum, and stage. The main emphasis of the analysis was defining criteria for selecting the patients who should be treated with abdominopelvic irradiation. This was accomplished when patients treated between 1971 and 1978 were grouped according to histologic findings as well as stage and residuum and the criteria were validated with a high degree of reproducibility in patients treated 1979 to 1981. The group of patients in whom abdominopelvic irradiation was indicated as definitive postoperative treatment comprised approximately one third of the overall patient population and their 5-year survival rate exceeded 70%. Serious bowel or liver toxicity occurred in 4% of patients.

Entities:  

Mesh:

Year:  1985        PMID: 3919934     DOI: 10.1002/1097-0142(19850501)55:9+<2285::aid-cncr2820551436>3.0.co;2-4

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  Intensity-modulated whole abdomen irradiation following adjuvant carboplatin/taxane chemotherapy for FIGO stage III ovarian cancer : four-year outcomes.

Authors:  Nathalie Rochet; Katja Lindel; Sonja Katayama; Kai Schubert; Klaus Herfarth; Andreas Schneeweiss; Christoph Sohn; Wolfgang Harms; Juergen Debus
Journal:  Strahlenther Onkol       Date:  2015-03-19       Impact factor: 3.621

2.  Common emergencies in cancer medicine: infectious and treatment-related syndromes, Part II.

Authors:  C R Thomas; K J Stelzer; J G Douglas; W J Koh; L V Wood; R Panicker
Journal:  J Natl Med Assoc       Date:  1994-11       Impact factor: 1.798

3.  Results of ovary tumor treatment with abdominally administered (198)Au evaluated on the basis of long term follow up.

Authors:  Mihály Patyánik; Arpád Mayer; István Polgár
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

Review 4.  Pharmacoeconomic considerations in treating ovarian cancer.

Authors:  D Bodurka-Bevers; C C Sun; D M Gershenson
Journal:  Pharmacoeconomics       Date:  2000-02       Impact factor: 4.981

5.  Abdominopelvic FLASH Irradiation Improves PD-1 Immune Checkpoint Inhibition in Preclinical Models of Ovarian Cancer.

Authors:  Joshua T Eggold; Stephanie Chow; Stavros Melemenidis; Jinghui Wang; Suchitra Natarajan; Phoebe E Loo; Rakesh Manjappa; Vignesh Viswanathan; Elizabeth A Kidd; Edgar Engleman; Oliver Dorigo; Billy W Loo; Erinn B Rankin
Journal:  Mol Cancer Ther       Date:  2021-12-05       Impact factor: 6.009

6.  The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): A randomized phase III NRG/Gynecologic Oncology Group (GOG) study.

Authors:  Nick M Spirtos; Danielle Enserro; Howard D Homesley; Susan K Gibbons; David Cella; Robert T Morris; Koen DeGeest; Roger B Lee; David S Miller
Journal:  Gynecol Oncol       Date:  2019-04-30       Impact factor: 5.482

7.  Accelerated large volume irradiation with dynamic Jaw/Dynamic Couch Helical Tomotherapy.

Authors:  Sonja Krause; Sebastian Beck; Kai Schubert; Steffen Lissner; Susanta Hui; Klaus Herfarth; Juergen Debus; Florian Sterzing
Journal:  Radiat Oncol       Date:  2012-11-12       Impact factor: 3.481

8.  Risk stratification of abdominopelvic failure for FIGO stage III epithelial ovarian cancer patients: implications for adjuvant radiotherapy.

Authors:  Jee Suk Chang; Woong Sub Koom; Sang Wun Kim; Sunghoon Kim; Yong Bae Kim; Young Tae Kim; Gwi Eon Kim
Journal:  J Gynecol Oncol       Date:  2013-04-05       Impact factor: 4.401

9.  Phase II study evaluating consolidation whole abdominal intensity-modulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III--the OVAR-IMRT-02 Study.

Authors:  Nathalie Rochet; Meinhard Kieser; Florian Sterzing; Sonja Krause; Katja Lindel; Wolfgang Harms; Michael H Eichbaum; Andreas Schneeweiss; Christof Sohn; Juergen Debus
Journal:  BMC Cancer       Date:  2011-01-28       Impact factor: 4.430

10.  Adjuvant whole abdominal intensity modulated radiotherapy (IMRT) for high risk stage FIGO III patients with ovarian cancer (OVAR-IMRT-01) - Pilot trial of a phase I/II study: study protocol.

Authors:  Nathalie Rochet; Alexandra D Jensen; Florian Sterzing; Marc W Munter; Michael H Eichbaum; Andreas Schneeweiss; Christof Sohn; Juergen Debus; Wolfgang Harms
Journal:  BMC Cancer       Date:  2007-12-19       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.